医薬経済は医療・医薬を取り巻く環境の“いま”にフォーカス!

MENU

RISFAX August 18, 2017

日本語

Cos-effectiveness assessment: A big gulf in how to reflect in drug pricing
The pharma industry says “Within the scope of premium rate”, and the payers keep “bold reductions” in mind

Japan Pharmaceutical Association (JPA) president Yamamoto: AISEI whose explanation about replaced claims is ambiguous, “disagreeable”